Skip to main content
OpenTrials
Completed

NCT Number: NCT03368573

QbTest Utility for Optimising Treatment in ADHD (QUOTA)

Attention Deficit/Hyperactivity Disorder (ADHD) is a condition that affects 3-5% of young people under 18-years-old.

Young people with ADHD have difficulties with attention, impulsivity and hyperactivity that make it harder for them to learn, form relationships and prepare for adulthood. Clinical guidelines state that young people taking medication for ADHD should be closely monitored and have their medication reviewed regularly to ensure they receive the correct dose to improve their symptoms. However, many young people aren't monitored as closely as guidelines recommend. This can lead to lack of improvement or worsening of symptoms meaning that children may not experience the benefits of medication as quickly as they should. At the moment, assessing whether or not medication is working relies on the opinions of teachers and parents, collected through questionnaires. The difficulties of this are: differences of opinion between people, lack of information provided by them, and not returning the questionnaires. A test performed on a computer (QbTest) provides doctors with a report of the young person's symptoms and can therefore show whether medication is working. This may help doctors reach accurate decisions about medication dose more quickly, reducing the need for questionnaires. The study team met with families and young people with ADHD and medical experts and developed a procedure for using QbTest to measure medication effects. The study team will measure how well this procedure works in the real world by asking a group of young people to complete the test when they first start taking medication and at their follow-up appointments. The study team will ask doctors and families/young people for their opinions on the procedure.

The study team shall share our findings with other researchers and with the public by attending local support groups and providing summaries of the study results. The findings will be used to prepare for a future study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ADHD Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Mental Disorders Neurodevelopmental Disorders

Age range

6 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nottinghamshire Healthcare NHS Foundation Trust

Nottingham, NG3 6AA, United Kingdom

About this study

The primary objective of the study is to assess the feasibility and acceptability of the study design using a feasibility RCT.

The end-points to assess this objective are:

  • Acceptability of randomisation. The number of patients who do not participate and state randomisation as the reason for non-participation. The study team shall also monitor drop-out rates immediately after randomisation and the number of errors in randomisation at each site.
  • Acceptability of study design. The number of eligible patients at each site and the numbers who consent to take part/withdraw. Withdrawal rates will be recorded alongside time point in the trial to ascertain acceptability of the study duration.
  • Acceptability of outcome measures. Completion rates for outcomes to determine most appropriate methods of data collection.
  • Acceptability/feasibility of protocol. Record non-adherence of healthcare professionals to the protocol and explore reasons.
  • Feasibility of future RCT. Estimate the hours per week needed to run the RCT and therefore the number of research assistants/fellows required and time commitment required by HCPs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female, aged 6-17 years (at the time of consent).
  • Participant is willing and able to give informed consent for participation in the study (if over 16-years).
  • Parental consent for children and young people aged under 16-years-old.
  • Referred to CAMHS or Community Pediatric services and diagnosed with ADHD.
  • Clinician and family (parent/carer and young person/child) agreement to commence stimulant medication for ADHD symptoms.

Exclusion criteria

  • Unable to give informed consent
  • Severe learning difficulty
  • Not started on stimulant medication (either not started on medication at all or started on a non-stimulant medication)
  • Non-fluent English

Treatment and study plan

QbTest

Device

QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.

Primary outcomes

  1. SNAP-IV

    Time frame: Follow up 2 (8-10 weeks)

    SNAP-IV is a short questionnaire designed to assess ADHD symptoms, with established validity, reliability and use in clinical and research settings. Completed by Parents and Teachers.

Secondary outcomes

  1. SDQ

    Time frame: Baseline (0 weeks), Follow up 2 (8-10 weeks)

    The SDQ is a short, well validated and well used clinical and research measure that assesses a range of behavioural and emotional issues in children and young people. Completed by parents and teachers.

  2. CHU9D

    Time frame: Baseline (0 weeks), Follow up 1 (2-4 weeks), Follow up 2 (8-10 weeks)

    a short (5 minute) measure of quality of life. The CHU9D has been designed for use with children and young people and is very easy to complete

  3. CGI (Clinical Global Impressions Scale)

    Time frame: Baseline (0 weeks), Follow up 2 (8-10 weeks)

    Clinicians will be asked to complete the CGI. The CGI takes no longer than 5 minutes to complete and measures symptom severity and improvement due to medication.

  4. Health Economic Outcome

    Time frame: Follow up 2 (8-10 weeks)

    Measure of use of Health Services

  5. Side Effects Questionnaire

    Time frame: Follow up 1 (2-4 weeks) and Follow up 2 (8-10 weeks)

    To measure medication side effects

  6. Medication adherence

    Time frame: Follow up 1 (2-4 weeks) and Follow up 2 (8-10 weeks)

    To look adherence to medication

  7. Qualitative Interviews

    Time frame: Follow up 2 (8-10 weeks)

    To look at the acceptability of the intervention

Sponsors and collaborators

Lead sponsor

Nottinghamshire Healthcare NHS Trust

Other Gov

Registry information

Official study title

Optimising Medication Management in Children and Young People With Attention Deficit Hyperactivity Disorder (ADHD) Using an Objective Measure of Attention, Impulsivity and Activity (QbTest): a Feasibility Study

Acronym: QUOTA

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Dec 11, 2017
Registry last updated
Mar 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.